在心肺bypass-studies Argatroban作为一个潜在的抗凝狗模型。

文章的细节

引用

复制到剪贴板

酒井法子M, Ohteki H,成田Y, Naitoh K,伊藤Natsuaki M T

在心肺bypass-studies Argatroban作为一个潜在的抗凝狗模型。

Cardiovasc Surg. 1999年3月,7 (2):187 - 94。

PubMed ID

10353669 (在PubMed

]

文摘

在日本Argatroban是一个选择性的凝血酶抑制剂合成。Argatroban为凝血酶具有高度的亲和力,并显著抑制thrombin-induced反应,被用于artherosclerosis闭塞性脉管炎患者。argatroban的效率,而不是肝素的抗凝狗心肺旁路模式探索。在第一项研究中,argatroban还丸+注入1 h在心肺旁路剂量的每分钟+ 10 microg 1.0毫克/公斤,2.0毫克+ 10 microg每分钟和3.0毫克/公斤+ 10 microg /公斤每分钟每组(n = 2)。激活凝血时间和动脉气体分析事先和10分钟之后。在第二个研究中,有四组。在第一组(n = 5),没有使用和肝素涂层体外电路(2毫克/公斤)是用作抗凝剂。在第二组(n = 5),使用涂布体外电路和使用肝素抗凝(2毫克/公斤)。在第三组(n = 3),没有涂体外电路使用和argatroban + 10 microg(2.0毫克/公斤/ min)是用作抗凝剂。第四组(n = 5),使用涂布体外电路使用和argatroban + 10 microg(2.0毫克/公斤/ min)作为抗凝剂。 All animals were perfused for 120 min at 40 ml/kg per minute. Platelet count, activated clotting time, thrombin-antithrombin III complex, antithrombin III, fibrinogen, fibrinogen degradation products and C3a were measured to evaluate platelet, coagulofibrinolytic and the complement system. Activated clotting time values and the effect of argatroban during cardiopulmonary bypass indicated a dose-dependent response. The next highest dosing group (2.0 mg + 10 microg/kg per minute) had activated clotting time values of 250-300 seconds during cardiopulmonary bypass, and fell after reaching near-normal levels within 60 minutes. No clots were noted in the extracorporeal circuit. The argatroban group showed lower levels in their coagulofibrinolytic system compared with the heparin group. The platelet count remained at a high level in the argatroban group. It is concluded that the combination of heparinized cardiopulmonary bypass circuits, and the use of argatroban as an anticoagulant, is safe and reduces the activation of coagulation and fibrinolytic systems and preserves platelet count.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Argatroban	凝血酶原	蛋白质	人类	是的	抑制剂	细节